Phospho-NMDAε2 (Ser1303) Rabbit Polyclonal Antibody

Description

EnkiLife offers the Phospho-NMDAε2 (Ser1303) Rabbit Polyclonal Antibody. This antibody reacts with Human,Mouse,Rat species and is suitable for WB,ELISA application. Alternative Names of Immunogen: GRIN2B; NMDAR2B; Glutamate [NMDA] receptor subunit epsilon-2; N-methyl D-aspartate receptor subtype 2B; NMDAR2B; NR2B; N-methyl-D-aspartate receptor subunit 3; NR3; hNR3. The product boasts remarkable high specificity, outstanding reproducibility, and exceptional affinity, making it a reliable and superior choice for your needs. Dilution Ratio: WB 1:500-1:2000,ELISA 1:20000-1:40000 Background: N-methyl-D-aspartate (NMDA) receptors are a class of ionotropic glutamate receptors. NMDA receptor channel has been shown to be involved in long-term potentiation, an activity-dependent increase in the efficiency of synaptic transmission thought to underlie certain kinds of memory and learning. NMDA receptor channels are heteromers composed of three different subunits: NR1 (GRIN1), NR2 (GRIN2A, GRIN2B, GRIN2C, or GRIN2D) and NR3 (GRIN3A or GRIN3B). The NR2 subunit acts as the agonist binding site for glutamate. This receptor is the predominant excitatory neurotransmitter receptor in the mammalian brain. [provided by RefSeq, Jul 2008],function:NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine.,similarity:Belongs to the glutamate-gated ion channel (TC 1.A.10) family.,subunit:Forms heteromeric channel of a zeta subunit (GRIN1), a epsilon subunit (GRIN2A, GRIN2B, GRIN2C or GRIN2D) and a third subunit (GRIN3A or GRIN3B). Found in a complex with GRIN1 and GRIN3B. Found in a complex with GRIN1, GRIN3A and PPP2CB. Interacts with PDZ domains of INADL and DLG4. Interacts with HIP1 (By similarity). Interacts with MAGI3.,tissue specificity:Primarily found in the fronto-parieto-temporal cortex and hippocampus pyramidal cells, lower expression in the basal ganglia., Research Area: Neuroactive ligand-receptor interaction;Long-term potentiation;Alzheimer's disease;Amyotrophic lateral sclerosis (ALS);Huntington's disease;Systemic lupus erythematosus;